{"entity":{"id":"nct05192486","kind":"trial","name":"A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)","aka":[],"tldr":"A phase 1/2 trial of GNC-038 in diffuse large B-cell lymphoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) is a phase 1/2 interventional study registered as NCT05192486 by Sichuan Baili Pharmaceutical Co., Ltd., with 12 participants enrolled, started 2022-08-10 and due to reach its primary completion in 2025-12. Interventions recorded: GNC-038.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05192486","url":"https://clinicaltrials.gov/study/NCT05192486"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05192486","phase":"1/2","setting":"An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Tetra-specific Antibody GNC-038 in Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":12,"outcomes":[]},"route":"/trials/nct05192486/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}